09-01-2017

IRE-ELiT S.A. selects Cardinal Health as the exclusive U.S. distributor of the Galli Eo® 68Ge / 68Ga generator

IRE-ELiT S.A. selects Cardinal Health as the exclusive U.S. distributor of the Galli Eo® 68Ge / 68Ga generator

IRE-ELiT S.A. (Environment & Lifescience Technology) selects Cardinal Health as the exclusive U.S. distributor of the Galli Eo® 68Ge / 68Ga generator


FLEURUS, Belgium, August 17th, 2017 —IRE-ELiT S.A. (Environment & Lifescience Technology) today announced that it has selected Cardinal Health, the largest national radiopharmacy network with the industry’s most comprehensive portfolio of radiopharmaceuticals in the U.S., as the exclusive distributor for Galli Eo® germanium-68 / gallium-68 (68Ge / 68Ga) generator in the U.S. and its territories including Puerto Rico.


IRE-ELiT has developed and is currently producing the Galli Eo® generator, for which a type II DMF has been submitted to the FDA (#031715) in May this year. Upon IRE-ELiT receiving the proper regulatory approval Cardinal Health will begin distributing the generator in the U.S.


“Gallium-68 is a radioisotope for Positron-emission tomography (PET) imaging functional technique with a high degree of precision to identify certain cancerous lesions like in recurrent prostate cancer. Its half-life is also very short but it has the advantage of being obtained more easily and at a lower cost through a germanium-68 / gallium-68 generator,” said Jean-Michel Vanderhofstadt, CEO – General Manager IRE – IRE ELiT.


To facilitate the preparation of radiopharmaceuticals using gallium-68, the Galli Eo® generator is a fully integrated, closed system to get rapidly, highly concentrated and very pure preparations minimizing the loss of activity. The innovative design limits the risk of error and contamination for the benefit of patients and users.


“This generator is attracting increased interest because it allows for simple and fast preparation of 68Ga -radiopharmaceuticals for PET imaging, which is showing promise in oncology imaging,” said Tiffany Olson, president of Nuclear Pharmacy Services at Cardinal Health. “Through this agreement, Cardinal Health will distribute IRE EliT’s new Galli Eo® 68Ge / 68Ga generator so we can help provide customers with cutting-edge technology for use with 68Ga imaging agents of the future.”


This deal reflects the ambitions of IRE-ELit to have a global dimension building a growth strategy in partnership with major players in Radiopharmaceuticals like Cardinal Health in the U.S., allowing for fast market penetration. As part of the agreement, Cardinal Health will distribute the Galli Eo® in support of clinical investigational trials, pre-commercial research and post-approval commercial sales in the U.S.


About IRE-ELiT S.A. (Environment & Lifescience Technology)


IRE ELiT, the Institute for Radioelement subsidiary, is an innovative radiopharmaceutical company that develops, produces and commercializes simple and premium solutions for Nuclear Medicine. Its portfolio is supported by R&D team fully committed in research programs with several universities and academic centers across the world. This cooperation is a key factor to develop new radiopharmaceuticals (like generators of Ga-68 & Re-188) keeping in mind a cost effective approach for radiopharmacies.


Steeped in its corporate culture, IRE ELiT places quality, reliability and services at the center of all its concerns to secure the supply and easy use of radiopharmaceuticals for its customers worldwide.


Founded in 2010, IRE ELiT has its headquarters and facilities in Fleurus, Belgium, able to manufacture both diagnostics and therapeutic NM products, employs 35 persons, has created a large distributors network (Australia, Austria, Canada, Italy, Middle East, Nordics…). For more information, please visit: www.ire.eu


Contact Media: IRE ELiT - Bérénice PIGNOL - phone: +32 4 71 70 62 44 - email: berenice.pignol@ire-elit.eu 


Feel free to download this media release in PDF format: IRE-ELit press release

IRE - Institute for Radioelements IRE Elit - Environement and lifescience Technology